Evolus (NASDAQ:EOLS) PT Lowered to $7.00

Evolus (NASDAQ:EOLS) had its price objective decreased by HC Wainwright from $15.00 to $7.00 in a report published on Tuesday, The Fly reports. HC Wainwright currently has a buy rating on the stock.

Several other equities research analysts have also issued reports on EOLS. Barclays decreased their price target on shares of Evolus from $9.00 to $4.00 and set an underweight rating for the company in a research note on Wednesday, May 13th. Mizuho reduced their price objective on shares of Evolus from $10.00 to $8.00 and set a buy rating for the company in a research note on Tuesday, May 12th. Stifel Nicolaus reduced their price objective on shares of Evolus from $30.00 to $25.00 and set a buy rating for the company in a research note on Thursday, April 16th. SunTrust Banks reduced their price objective on shares of Evolus from $18.00 to $12.00 and set a buy rating for the company in a research note on Tuesday, May 12th. Finally, SVB Leerink reduced their price objective on shares of Evolus from $25.00 to $15.00 and set an outperform rating for the company in a research note on Friday, April 3rd. Two research analysts have rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Evolus has a consensus rating of Hold and a consensus target price of $11.88.

NASDAQ:EOLS opened at $3.03 on Tuesday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 5.02 and a current ratio of 5.58. The firm has a market cap of $112.99 million, a price-to-earnings ratio of -0.89 and a beta of 3.19. Evolus has a 52 week low of $3.00 and a 52 week high of $20.27. The firm has a 50-day moving average price of $5.05 and a two-hundred day moving average price of $6.86.

Evolus (NASDAQ:EOLS) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.72) by ($0.03). Evolus had a negative return on equity of 197.30% and a negative net margin of 217.51%. The company had revenue of $10.50 million for the quarter, compared to analysts’ expectations of $16.91 million. As a group, sell-side analysts forecast that Evolus will post -2.58 earnings per share for the current year.

A number of large investors have recently made changes to their positions in the business. Rhumbline Advisers boosted its holdings in Evolus by 11.2% in the 4th quarter. Rhumbline Advisers now owns 16,448 shares of the company’s stock valued at $200,000 after purchasing an additional 1,651 shares during the period. Royal Bank of Canada lifted its holdings in shares of Evolus by 55.6% during the 1st quarter. Royal Bank of Canada now owns 7,141 shares of the company’s stock worth $30,000 after acquiring an additional 2,553 shares during the last quarter. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Evolus by 19.7% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 18,549 shares of the company’s stock worth $77,000 after acquiring an additional 3,049 shares during the last quarter. Metropolitan Life Insurance Co NY bought a new stake in shares of Evolus during the 1st quarter worth $83,000. Finally, UBS Group AG lifted its holdings in shares of Evolus by 5.1% during the 4th quarter. UBS Group AG now owns 83,565 shares of the company’s stock worth $1,017,000 after acquiring an additional 4,076 shares during the last quarter. 42.43% of the stock is owned by hedge funds and other institutional investors.

About Evolus

Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.

Further Reading: Marijuana Stocks

The Fly

Analyst Recommendations for Evolus (NASDAQ:EOLS)

Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.